InvestorsHub Logo
Followers 27
Posts 896
Boards Moderated 0
Alias Born 08/30/2006

Re: None

Sunday, 10/26/2014 7:34:46 AM

Sunday, October 26, 2014 7:34:46 AM

Post# of 403018
"This is an historic event and a proud day for Cellceutix shareholders as we have proven the efficacy of one dose of our novel drug Brilacidin to be comparable to seven days of therapy with the blockbuster antibiotic daptomycin to treat ABSSSI with zero drug-related SAEs," commented Leo Ehrlich, Chief Executive Officer of Cellceutix.

Get a 2nd citizenship for your children and grandkids if you love them. Escaping the once great USA will be the gift of a lifetime.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News